Luteinizing Hormone-releasing Hormone Agonists Versus Orchiectomy in the Treatment of Prostate Cancer: A Systematic Review

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Feb 23

PMID 36814583

Authors

Xianlu Zhang

Gejun Zhang

Jianfeng Wang

Yanli Wang

Affiliations

Soon will be listed here.

Abstract

Background: Orchiectomy has been replaced by medication represented by luteinizing hormone-releasing hormone (LHRH) agonist as the first-line therapy for androgen deprivation therapy (ADT). After the wide application of LHRH agonist, the side-effects of long-term ADT were noticed. It is time to reconsider the role of medication and surgeries in the treatment of prostate cancer.

Methods: Embase, Pubmed, Web of science and Cochrane library were searched for relevant trials. Quality of the studies and risk of bias were assessed by using the Newcastle-Ottawa Scale (NOS). Therapeutic and adverse effects, as well as long-term metabolic adverse effects were extracted from the selected studies. The data synthesized in meta-analyses were performed with R software (4.2.1). Risk ratio (RR) with its 95% confidence interval (CI) was calculated by combining outcome data including complete and partial response rate, progression rate, death rate and adverse effects such as hot flash and increase in pain. Descriptive analysis was performed among the prostate specific antigen (PSA), testosterone and metabolic adverse effects due to a lack of homogeneity of frailty measures.

Results: 1,711 participants from 11 studies were included in our systematic review. 1,258 patients from six studies were included in the meta-analysis. Based on the meta-analysis, the therapeutic and adverse outcomes included overall response rate, complete response rate, partial response rate, stable rate, progression rate, death rate and hot flashes. No statistical significance was observed between LHRH agonists and orchiectomy. Compared with surgery, LHRH agonist elevated the risk of the increase in pain. In descriptive analysis, it was shown that the therapeutic effects between PSA and testosterone also showed no significant difference. Both groups had lipid and glucose metabolic disorders, and a few studies reported worse lipid metabolic performance in orchiectomy group and worse insulin resistance in LHRH agonist group.

Conclusion: We found that the therapeutic outcomes were similar between the two options. The results of lipid and glucose metabolic abnormality were controversial in existing studies. The direct comparison studies on metabolic adverse effects should be performed in the future. The therapeutic, metabolic, psychological and economical effects should be considered before applying ADT methods.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022365891.

Citing Articles

Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses.

Anderson G Explor Target Antitumor Ther. 2023; 4(5):962-993.

PMID: 37970210 PMC: 10645470. DOI: 10.37349/etat.2023.00176.

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review.

Zhang X, Zhang G, Wang J, Wang Y Front Endocrinol (Lausanne). 2023; 14:1131715.

PMID: 36814583 PMC: 9939757. DOI: 10.3389/fendo.2023.1131715.

References

Orakwe D, Tijani K, Jeje E, Ogunjimi M, Rufus W, Alabi T . Bilateral subcapsular orchiectomy versus bilateral total orchiectomy: Comparison of the quality of life post-orchiectomy. Niger Postgrad Med J. 2018; 25(1):43-47. DOI: 10.4103/npmj.npmj_169_17. View

McLeod D . Antiandrogenic drugs. Cancer. 1993; 71(3 Suppl):1046-9. DOI: 10.1002/1097-0142(19930201)71:3+<1046::aid-cncr2820711424>3.0.co;2-m. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Saad F, Aversa A, Isidori A, Gooren L . Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012; 8(2):131-43. PMC: 3296126. DOI: 10.2174/157339912799424573. View

Maatman T, Gupta M, Montie J . Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol. 1985; 133(4):620-1. DOI: 10.1016/s0022-5347(17)49115-4. View

Parmar H, Edwards L, Phillips R, Allen L, Lightman S . Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol. 1987; 59(3):248-54. DOI: 10.1111/j.1464-410x.1987.tb04616.x. View

Ryan P, Peeling W . U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy. Am J Clin Oncol. 1988; 11 Suppl 2:S169-72. DOI: 10.1097/00000421-198801102-00039. View

Vogelzang N, Chodak G, Soloway M, Block N, Schellhammer P, Smith Jr J . Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995; 46(2):220-6. DOI: 10.1016/s0090-4295(99)80197-6. View

Vihko P, Harkonen P, Soronen P, Torn S, Herrala A, Kurkela R . 17 beta-hydroxysteroid dehydrogenases--their role in pathophysiology. Mol Cell Endocrinol. 2004; 215(1-2):83-8. DOI: 10.1016/j.mce.2003.11.021. View

10.

Ostergren P, Kistorp C, Fode M, Henderson J, Bennedbaek F, Faber J . Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J Urol. 2016; 197(6):1441-1447. PMC: 5433917. DOI: 10.1016/j.juro.2016.12.003. View

11.

Zhang X, Zhang G, Wang J, Wang Y . Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review. Front Endocrinol (Lausanne). 2023; 14:1131715. PMC: 9939757. DOI: 10.3389/fendo.2023.1131715. View

12.

Wilson R, Taaffe D, Newton R, Hart N, Lyons-Wall P, Galvao D . Using Exercise and Nutrition to Alter Fat and Lean Mass in Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review. Nutrients. 2021; 13(5). PMC: 8156712. DOI: 10.3390/nu13051664. View

13.

El-Rayes B, Hussain M . Hormonal therapy for prostate cancer: past, present and future. Expert Rev Anticancer Ther. 2002; 2(1):37-47. DOI: 10.1586/14737140.2.1.37. View

14.

Ostergren P, Kistorp C, Fode M, Bennedbaek F, Faber J, Sonksen J . Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU Int. 2018; 123(4):602-611. DOI: 10.1111/bju.14609. View

15.

Moreau J, Delavault P, Blumberg J . Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther. 2006; 28(10):1485-508. DOI: 10.1016/j.clinthera.2006.10.018. View

16.

Spetz A, Hammar M, Lindberg B, Spangberg A, Varenhorst E . Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001; 166(2):517-20. View

17.

Higano C . Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003; 61(2 Suppl 1):32-8. DOI: 10.1016/s0090-4295(02)02397-x. View

18.

Issa M, Lendvay T, Bouet R, Young M, Petros J, Marshall F . Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image. J Urol. 2005; 174(3):893-7. DOI: 10.1097/01.ju.0000172567.09442.b0. View

19.

Kaisary A, Tyrrell C, Peeling W, Griffiths K . Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991; 67(5):502-8. DOI: 10.1111/j.1464-410x.1991.tb15195.x. View

20.

Parmar H, Phillips R, Lightman S, Edwards L, Allen L, Schally A . Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet. 1985; 2(8466):1201-5. DOI: 10.1016/s0140-6736(85)90739-1. View